glp-1 approval How Employers Can Optimize Benefits in the Era of GLP-1s GLP-1 Medications for Weight Loss:

Occasionally, GLP-1s affect intestinal motility or secretions, contributing to diarrhea [44]

Moreover, even when prescribed, Hispanic and non-Hispanic Black individuals are more likely to report cost-prohibitive access barriers to diabetes medications, increasing risk in these populations for diabetes-related complications and mortality.[85] As future research aims to comprehensively assess the full scope of GLP-1RAs benefits and risks, it is imperative that such studies include the populations with the greatest potential for benefit and explore strategies to mitigate disparities in post-marketing access to these therapies.[86] CONCLUSIONS Since their introduction two decades ago, GLP-1RAs have expanded from glycemic control to treat a variety of conditions in individuals without diabetes, including weight management, cardiovascular risk reduction, and obstructive sleep apnea

In rats, the LWP-induced GLP-1 secretion further improves glucose tolerance and enhances insulin secretion, an effect that is blocked by pre-administration of the GLP-1R antagonist exendin (939) [306]

Cellular Neuroadaptations to Chronic Opioids: Tolerance, Withdrawal and Addiction

Readers should review current FDA updates regarding compounded GLP-1 products